Abstract | BACKGROUND: AIM: SUBJECTS AND METHODS: We conducted an electronic search for articles published through September 2012 without restrictions. Every included study was to report risk estimates with 95% confidence intervals for the association between metabolic syndrome and prostate cancer. RESULTS: The final number of papers included in the meta-analysis was 14, all published in English, with 4728 prostate cancer cases. Metabolic syndrome was associated with a 12% increase in prostate cancer risk (p=0.231), that was lower in cohort studies (7 studies, RR=1.04, p=0.791) than other studies (RR=1.23, p=0.125). The association was significant in the 8 European studies (RR=1.30, p=0.034), but not in the 4 U.S. or 2 Asiatic studies. The risk estimates of prostate cancer for higher values of body mass index, dysglycemia or dyslipidemia (high triglycerides, low HDL-cholesterol) were not significant; on the contrary, hypertension and waist circumference >102 cm were associated with a significant 15% (p=0.035) and 56% (p=0.007) greater risk of prostate cancer, respectively. CONCLUSIONS:
|
Authors | K Esposito, P Chiodini, A Capuano, G Bellastella, M I Maiorino, E Parretta, A Lenzi, D Giugliano |
Journal | Journal of endocrinological investigation
(J Endocrinol Invest)
Vol. 36
Issue 2
Pg. 132-9
(Feb 2013)
ISSN: 1720-8386 [Electronic] Italy |
PMID | 23481613
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Topics |
- Case-Control Studies
- Cohort Studies
- Humans
- Male
- Metabolic Syndrome
(diagnosis, epidemiology, physiopathology)
- Prostatic Neoplasms
(diagnosis, epidemiology, physiopathology)
- Risk Factors
|